Radiopharm Theranostics (ASX:RAD) raise $5 million via the execution of a subscription agreement for a private placement of 133 million ordinary shares to Lantheus Holdings, according to a Friday Australian bourse filing.
After the placement, Lantheus' shareholding in the firm rose to 12.16%.
The placement was completed at an issue price of AU$0.06 apiece, and under Radiopharm's existing
placement capacity.
The radiopharmaceuticals firm will use the funds for the development of its clinical pipeline.
The placement replaces the six-month options that it issued in August 2024.
The firm's shares surged 58% in recent trade on Friday.